Please login to the form below

Not currently logged in
Email:
Password:

Amgen appoints CEO Robert Bradway to chair of board

Replaces Kevin Sharer who retires

Robert Bradway, AmgenAmgen's CEO Robert Bradway (pictured) has been named the company's chair of the board of directors, replacing Kevin Sharer who will retire at the end of the year.

The move follows Bradway's replacement of Sharer as Amgen's CEO in May, 2012, completing a succession process that was originally announced a year ago.

Bradway joined the company in 2006 as VP, operations strategy, before being appointed to executive VP and chief financial officer and then chief operating officer. Prior to joining the company, he was managing director of Morgan Stanley.

Sharer's departure ends his 20-year involvement with Amgen, including 12 years as CEO from 2000. During his time as head of the company, its annual revenue grew from $3.6bn to $16bn.

Bradway's appointment wasn't the only change at the top for Amgen, with director Vance Coffman appointed lead independent director.

"On behalf of the board and all of Amgen, we look forward to Vance Coffman's continued contributions as the new lead independent director," said Bradway, "and we thank Kevin Sharer for his 20 years of dedicated service and his contributions to the company and the patients we serve."

In addition, Amgen also announced the appointment of a new board member, with former CEO at toy company Mattel, Robert Eckert, to serve on the audit and corporate responsibility and compliance committees of the board.

"We are pleased to welcome Bob Eckert to the Amgen Board. Bob has significant experience and a superb track record of leading global companies during a long and successful career," said Bradway.

17th December 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics